Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Nitrogen containing other than solely as a nitrogen in an...
Reexamination Certificate
2007-02-22
2011-10-25
Gupta, Anish (Department: 1654)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Nitrogen containing other than solely as a nitrogen in an...
C514S660000, C514S661000, C514S675000, C514S676000, C514S690000, C514S691000, C544S387000, C548S453000, C548S466000
Reexamination Certificate
active
08044103
ABSTRACT:
The present invention provides 4-substituted-2-azetidinone compounds, bicyclic 2-5-diketopiperazine compounds, and pharmaceutical compositions thereof that are potent, safe and effective neuroprotective agents. Due to their strong central nervous system (CNS) activity, the compounds can be used to enhance memory and to treat a variety of neurological disorders. The compounds are particularly useful for treating neurological disorders caused by, or associated with, CNS trauma.
REFERENCES:
Azzouz, Mimoun “Gene Therapy for ALS: Progress and Prospects” Biochemical et Biophysica Acta (2006), vol. 1762 pp. 112-1127.
Citron, Martin. Alzheimer's Disease: Treatments in Discovery and Development. Nature Neurroscience Supplment. vol. 5, pp. 1055-1057. Nov. 2002.
Korczyn et al. ‘Emerging Therapies in the Pharmacological Treatment of Parkinson's Disease’ Drugs vol. 62, No. 5 pp. 775-786. 2002.
Margolis et al. ‘Diagonsis of Huntington Disease’ Clinical Chemistry, vol. 49, No. 10 pp. 1726-1732 (2003).
Patel et al. Pharmacotherapy of Cognitive Impariment in Alzheimer's Disease: A Review J. Geriatr. Psychiatry Neruol. vol. 8 pp. 81-95. 1995.
File Medline on STN An No. 2005478947. Simmons, Zachary. “Management Strageies for Patients with Amyotrphoic Lateral Sclerosis from diagnosis Through Death.” The Neurologist (Sep. 2005), vol. 11, No. 5, pp. 257-270. Abstract only.
Steinman et al. ‘How to Successfully Apply Animal Studies in Experimental Allergic Encephalomyelitis to Research on Multple Sclerosis’ Ann Neurol. vol. 60, pp. 12-21. 2006.
Zhang et al. “Oxidative Stress and Genetics in the Pathogenesis of Parkinson's Disease” Neurobiology of Disease. vol. 7, Issue 4, Aug. 2000, pp. 240-250.
Stoessl, Jon A. Poteinal Therapeutic Targets for Parkinson's Disease Expert Opin. Ther. Targets. vol. 12, No. 4, 2008, pp. 425-436.
Martin et al. Neurodegneration in Excitotoxicity, Global Cerbral Ischemia, and Target Deprivation: A Perspective on the Contributions of Apoptosis and Necrosis. Brain Research Bulletin. vol. 46. No. 4, pp. 281-309. 1998.
Mattson, Mark. “Pathway Towards and Away From Alzheimer's Disease.” Nature, vol. 430. pp. 631-639. Aug. 2004.
Araldi Gian Luca
Faden Alan I.
Kozikowski Alan P.
Georgetown University
Gupta Anish
Scully , Scott, Murphy & Presser, P.C.
LandOfFree
Cyclic dipeptides and azetidinone compounds and their use in... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Cyclic dipeptides and azetidinone compounds and their use in..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Cyclic dipeptides and azetidinone compounds and their use in... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4293022